
Opinion|Videos|February 18, 2025
The Future of Neurokinin-Targeted Therapies in Patients With VMS
Author(s)Alexa N. Fiffick, D.O., MBS, MSCP
A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How might these therapies fit into combination treatment strategies, and what combinations seem most promising?
- How do you see the broader implications of neurokinin-targeted therapies on patient outcomes and quality of life? What are the unmet needs with these therapies?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Real-World Data Shows Vision Decline as Copay Programs Run Dry | AAO 2025
2
AI and Ophthalmology: A Nearly Picture Perfect Kinda Match | AAO 2025
3
In Complement Inhibition Debate, Game Change Goes Against Too Little, Too Late | AAO 2025
4
Positive Results Reported for Hernexeos as a First-Line Treatment for NSCLC With HER2 Mutations
5